Both in Biotechnology
Humacyte vs Outlook Therapeutics
Over the past year HUMA returned −69.2% and OTLK returned −41.0%; their daily moves had a correlation of 0.07.
HUMA −69.2% OTLK −41.0%Growth of $1, one year, split-adjusted
| Metric | HUMA | OTLK |
|---|---|---|
| Price | $0.5327 | $0.6257 |
| Market cap | $148.0M | $152.3M |
| Today | −2.65% | +0.74% |
| 1 month | −18.1% | −3.0% |
| 6 months | −7.3% | +211.3% |
| Year to date | −44.5% | −60.4% |
| 1 year | −69.2% | −35.5% |
| Revenue growth (YoY) | +34.9% | −99.4% |
| Gross margin | −203.2% | −95.0% |
| Net margin | −9064.5% | −233554.9% |
| P/E (TTM) | — | — |
| Price / sales | 69.8× | — |
| Net cash | $13.7M | -$7.0M |
| Dividend yield | — | — |
| Volatility (60d) | 87.0% | 116.1% |
| Short % of float | 13.0% | 38.8% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).